Ken Griffin Bluejay Diagnostics, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.38 - $0.87 $1,410 - $3,229
-3,712 Reduced 26.19%
10,462 $4,000
Q4 2022

Feb 14, 2023
BUY
$0.34 - $138.99 $4,819 - $1.97 Million
14,174 New
14,174 $5,000

About Bluejay Diagnostics, Inc.

BJDX Quotes by TradingView
  • Ticker BJDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 20,152,300
  • Market Cap $3.63M
  • Description
  • Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoass...
More about BJDX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email